Genomic Health (Nasdaq: GHDX) reported earnings on Feb. 6. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Genomic Health met expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue improved and GAAP earnings per share increased significantly.

Margins expanded across the board.

Revenue details
Genomic Health reported revenue of $53.4 million. The 17 analysts polled by S&P Capital IQ foresaw sales of $53.9 million. Sales were 13% higher than the prior-year quarter's $47.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
EPS came in at $0.08. The 12 earnings estimates compiled by S&P Capital IQ predicted $0.09 per share. GAAP EPS of $0.08 for Q4 were 60% higher than the prior-year quarter's $0.05 per share.

Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 86.2%, 470 basis points better than the prior-year quarter. Operating margin was 5.1%, 230 basis points better than the prior-year quarter. Net margin was 4.8%, 120 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $56.2 million. On the bottom line, the average EPS estimate is $0.08.

Next year's average estimate for revenue is $236.8 million. The average EPS estimate is $0.44.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 246 members out of 261 rating the stock outperform, and 15 members rating it underperform. Among 88 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 85 give Genomic Health a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Genomic Health is outperform, with an average price target of $26.75.

The biotechnology and health-care investing landscape is littered with also-rans and a few major winners. Is Genomic Health the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.